The past decade has witnessed the development and approval of selective estrogen receptor modulators (SREMs) to treat different estrogen-responsive conditions, including postmenopausal osteoporosis and breast cancer.381 SREMs are structurally diverse compounds that act either as ER agonists or antagonists by interacting with ERs in target organs. This evidence concerns the gene ESR1 and breast carcinoma.